Advanced non-viral gene delivery systems are expanding the range of indications and therapy modalities possible for the new generation of genetic medicines.

The right approaches are demonstrating that it is possible to breach the defensively designed blood-brain barrier despite its ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the Australian Therapeutic Goods Administration (TGA) has approved REDEMPLO® (plozasiran), a small interfering RNA (siRNA) medicine, ...

Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing ...

Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – ...

Bags and Builds cornhole tournament takes place Thursday, May 7 at 5:30 p.m. at South 40.

AstraZeneca has scrapped an asthma program after the FLAP inhibitor flopped in a phase 2 trial. | AstraZeneca has scrapped an ...

The trial will assess the tolerability, safety, pharmacodynamics, and pharmacokinetics of BW-50218 in participants.

With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, ...

Long-acting RNA interference therapy for hypertension could shift blood pressure control from daily pill-taking to scheduled, ...

The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.

Arrowhead Pharma (ARWR), and Novartis (NVS) are among winners of EU recommendations for their pharmaceuticals this week. Read ...